The Company has a pipeline of in-house and partnered therapeutics based on its proprietary gene silencing technology, DNA-directed RNA interference (ddRNAi), also known as expressed RNAi.
Benitec is developing novel treatments for chronic and life-threatening conditions.
Benitec has a robust intellectual property portfolio with exclusive worldwide rights for developing and commercializing all human therapeutic applications of ddRNAi technology.
The Company is pursuing focused in-house R&D programs in infectious diseases, cancer and chronic cancer-associated pain as well as partnered programs that have advanced to pre-clinical and/or clinical trials. Additionally, ddRNAi technology as a research tool is available through technology licensing.
November 25, 2011
Bioshares Investor Report: Benitec – Building Proof of Concept Data in Four Diseases
November 18, 2011
Chief Investigators Group - Investor Presentation
November 17, 2011
Chairmans Address AGM 2011
November 17, 2011
RD Update on Therapeutic Programs
September 19, 2011
ASX RELEASE :
Benitec Pain Program Receives Clinical Endorsement and Moves Towards the Clinic
August 24, 2011
Benitec's Appendix 4E and Full Year 2011 Statutory Accounts
August 10, 2011
August 8, 2011
July 27, 2011
Another Patent in Graham Family Allowed in US
Prices delayed by at least 20 minutes. Retrieving this share price indicates your acceptance of the terms.
Van Leeuwenhoeck Institute Report
Initiating coverage report on Benitec.
Download Report
Viriathus Overview Report
New York-based independent research firm Viriathus Research LLC has published a comprehensive report on Benitec.
Download Report
Corporate Presentation
CEO Peter French has presented to BioEquity Europe 2011 in Paris, France.
